Literature DB >> 9230787

Granulomatous amebic encephalitis due to Balamuthia mandrillaris (Leptomyxiidae): report of four cases from Mexico.

J M Riestra-Castaneda1, R Riestra-Castaneda, A A Gonzalez-Garrido, P Pena Moreno, A J Martinez, G S Visvesvara, F Jardon Careaga, J L Oropeza de Alba, S Gonzalez Cornejo.   

Abstract

In this report, we describe four cases of granulomatous amebic encephalitis caused by Balamuthia (Leptomyxid ameba) in four previously healthy Mexican patients. All four cases were characterized by focal neurologic signs, increased intracranial pressure, and cerebral hyperdense lesions in computed tomography scans of the head. These patients underwent craniotomies for evaluation of mass lesions for possible brain tumors. Granulomatous chronic inflammatory reaction and amebic trophozoites were found in brain biopsies. At autopsy, areas of hemorrhagic encephalomalacia were located in both basal frontal lobes, right parieto-occipital lobes, and, less often, in the brainstem and cerebellum. Angiitis, necrotizing granulomatous encephalitis, and large numbers of amebic trophozoites in perivascular spaces were present. Amebic trophozoites were seen in the left adrenal gland in one of the cases. The amebas in all four cases were identified as Balamuthia mandrillaris (Leptomyxiidae) based on their reactivity with the anti-Balamuthia (Leptomyxiidae) serum in an immunofluorescence test.

Entities:  

Mesh:

Year:  1997        PMID: 9230787     DOI: 10.4269/ajtmh.1997.56.603

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Balamuthia amebic encephalitis: radiographic and pathologic findings.

Authors:  John F Healy
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  Balamuthia mandrillaris amoebic encephalitis: an emerging parasitic infection.

Authors:  Francisco G Bravo; Carlos Seas
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

3.  Clinical case of cerebral amebiasis caused by E. histolytica.

Authors:  Cinthya A Maldonado-Barrera; Maria Del Rosario Campos-Esparza; Luis Muñoz-Fernández; Joaquin A Victoria-Hernández; Rafael Campos-Rodríguez; Patricia Talamás-Rohana; Javier Ventura-Juárez
Journal:  Parasitol Res       Date:  2011-08-26       Impact factor: 2.289

Review 4.  Increasing importance of Balamuthia mandrillaris.

Authors:  Abdul Matin; Ruqaiyyah Siddiqui; Samantha Jayasekera; Naveed Ahmed Khan
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

5.  Balamuthia mandrillaris amebic encephalitis.

Authors:  Maria T Perez; Larry M Bush
Journal:  Curr Infect Dis Rep       Date:  2007-07       Impact factor: 3.725

6.  Diagnosis of infections caused by pathogenic free-living amoebae.

Authors:  Bruno da Rocha-Azevedo; Herbert B Tanowitz; Francine Marciano-Cabral
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-02

7.  Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen Balamuthia mandrillaris.

Authors:  Matthew T Laurie; Corin V White; Hanna Retallack; Wesley Wu; Matthew S Moser; Judy A Sakanari; Kenny Ang; Christopher Wilson; Michelle R Arkin; Joseph L DeRisi
Journal:  mBio       Date:  2018-10-30       Impact factor: 7.867

Review 8.  Adrenal infections.

Authors:  William F Paolo; Joshua D Nosanchuk
Journal:  Int J Infect Dis       Date:  2006-02-17       Impact factor: 3.623

9.  Cutaneous balamuthiasis: A clinicopathological study.

Authors:  Patricia Alvarez; Carlos Torres-Cabala; Eduardo Gotuzzo; Francisco Bravo
Journal:  JAAD Int       Date:  2022-01-10

10.  Encephalomyelitis Caused by Balamuthia mandrillaris in a Woman With Breast Cancer: A Case Report and Review of the Literature.

Authors:  Juan Hu; Yiqi Zhang; Yongwei Yu; Huili Yu; Siruo Guo; Ding Shi; Jianqin He; Chi Hu; Jiqi Yang; Xueling Fang; Yonghong Xiao
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.